Switch theme
Sign up to access all valuation multiples
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.
2003
2
LTM Revenue $0.6M
Last FY EBITDA -$7.9M
$19.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cynata Therapeutics has a last 12-month revenue (LTM) of $0.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Cynata Therapeutics achieved revenue of n/a and an EBITDA of -$7.9M.
Cynata Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cynata Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $0.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$7.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | n/a | XXX | -$8.1M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$5.0M | XXX | -$6.3M | XXX | XXX | XXX |
| Net Margin | -778% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Cynata Therapeutics's stock price is AUD 0 (or $0).
Cynata Therapeutics has current market cap of AUD 40.7M (or $26.1M), and EV of AUD 30.2M (or $19.4M).
See Cynata Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $19.4M | $26.1M | XXX | XXX | XXX | XXX | $-0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Cynata Therapeutics has market cap of $26.1M and EV of $19.4M.
Cynata Therapeutics's trades at n/a EV/Revenue multiple, and -3.1x EV/EBITDA.
Equity research analysts estimate Cynata Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cynata Therapeutics has a P/E ratio of -5.2x.
See valuation multiples for Cynata Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $26.1M | XXX | $26.1M | XXX | XXX | XXX |
| EV (current) | $19.4M | XXX | $19.4M | XXX | XXX | XXX |
| EV/Revenue | 30.0x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -3.1x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -3.0x | XXX | XXX | XXX |
| EV/Gross Profit | 30.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.2x | XXX | -4.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCynata Therapeutics's last 12 month revenue growth is 976%
Cynata Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $4.0M for the same period.
Cynata Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cynata Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cynata Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 976% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $4.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| Orthocell | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cynata Therapeutics acquired XXX companies to date.
Last acquisition by Cynata Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Cynata Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cynata Therapeutics founded? | Cynata Therapeutics was founded in 2003. |
| Where is Cynata Therapeutics headquartered? | Cynata Therapeutics is headquartered in Australia. |
| How many employees does Cynata Therapeutics have? | As of today, Cynata Therapeutics has 2 employees. |
| Is Cynata Therapeutics publicy listed? | Yes, Cynata Therapeutics is a public company listed on ASX. |
| What is the stock symbol of Cynata Therapeutics? | Cynata Therapeutics trades under CYP ticker. |
| When did Cynata Therapeutics go public? | Cynata Therapeutics went public in 2007. |
| Who are competitors of Cynata Therapeutics? | Similar companies to Cynata Therapeutics include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Mesoblast. |
| What is the current market cap of Cynata Therapeutics? | Cynata Therapeutics's current market cap is $26.1M |
| What is the current revenue of Cynata Therapeutics? | Cynata Therapeutics's last 12 months revenue is $0.6M. |
| What is the current revenue growth of Cynata Therapeutics? | Cynata Therapeutics revenue growth (NTM/LTM) is 976%. |
| What is the current EV/Revenue multiple of Cynata Therapeutics? | Current revenue multiple of Cynata Therapeutics is 30.0x. |
| Is Cynata Therapeutics profitable? | Yes, Cynata Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
